Specialty Pharma Journal Specialty, Precision & Technology
WALTHAM, Mass., Dec. 13, 2018 /PRNewswire/ — Dragonfly Therapeutics, Inc. (“Dragonfly” or the “Company”), today announced it has licensed two TriNKET™ immunotherapy drug candidates to Celgene Corporation and its affiliates (“Celgene”) for $12m each plus prospective milestones and royalties. The licenses represent the first two of four hematological cancer targets …
Tag Archives: celgene
December, 2018
-
5 December
bluebird bio and Celgene Corporation Present Initial Data from Ongoing Phase 1 Study of Anti-BCMA CAR T Cell Therapy bb21217 in Patients with Multiple Myeloma
CAMBRIDGE, Mass. & SUMMIT, N.J.–(BUSINESS WIRE)–bluebird bio, Inc. (Nasdaq:BLUE) and Celgene Corporation (NASDAQ:CELG) announced initial data from the ongoing Phase 1 clinical study of bb21217 (CRB-402), an investigational next-generation anti-BCMA CAR T cell therapy being studied in patients with relapsed/refractory multiple myeloma. The data were presented by Nina Shah, M.D., …
November, 2018
-
15 November
Dragonfly and Celgene Expand Collaboration in Immunotherapies for Patients with Solid and Hematological Cancers
WALTHAM, Mass., Nov. 14, 2018 /PRNewswire/ — Dragonfly Therapeutics, Inc. (“Dragonfly” or the “Company”), today announced it entered into a new agreement with Celgene Corporation and its affiliates (“Celgene”) to discover, develop and commercialize innovative immunotherapies for patients with solid and hematological cancers. The new agreement builds upon Celgene’s existing …
October, 2018
-
24 October
Revlimid Demonstrated a Significant Improvement in Progression-Free Survival Compared with Observation in Patients with Smoldering Multiple Myeloma
SUMMIT, N.J.–(BUSINESS WIRE)–Celgene Corporation (NASDAQ: CELG) today announced results from an open-label phase II/III National Clinical Trials Network (NCTN) study led by the ECOG-ACRIN Cancer Research Group and sponsored by the National Cancer Institute (NCI), part of the National Institutes of Health. REVLIMID® (lenalidomide) was provided by Celgene under a clinical …
-
11 October
Recent Survey Reveals that Multiple Sclerosis Patients Want More Information on Brain Atrophy
SUMMIT, N.J.–(BUSINESS WIRE)–A new survey examines the topic of brain volume loss, known as brain atrophy, in people with multiple sclerosis. The survey findings, presented at ECTRIMS 2018, suggest that there is a high level of interest in better understanding how brain atrophy may impact disease progression. Sixty-three percent of …
-
10 October
Celgene’s Otezla Meets Primary Endpoint in Phase 3 Study in Moderate to Severe Scalp Psoriasis
SUMMIT, N.J.–(BUSINESS WIRE)–Celgene Corporation (NASDAQ:CELG) today announced results from the phase 3 STYLE study, which showed that OTEZLA® (apremilast) 30 mg twice daily achieved a highly statistically significant improvement in the primary endpoint of the Scalp Physician’s Global Assessment (ScPGA) response [defined as ScPGA score of clear (0) or almost clear …
September, 2018
-
21 September
Celgene Drops Option to License OncoMed’s Bispecific Antibody Navicixizumab
REDWOOD CITY, Calif., Sept. 20, 2018 (GLOBE NEWSWIRE) — OncoMed Pharmaceuticals Inc. (NASDAQ: OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, today announced that Celgene has notified OncoMed that due to strategic product portfolio considerations Celgene has decided not to exercise its option to license …
-
12 September
Celgene’s Otezla Showed Meaningful Improvements in Clinical and Quality-of-Life Measures of Psoriasis Beyond Those Captured by Assessing Skin Alone
SUMMIT, N.J.–(BUSINESS WIRE)–Celgene Corporation (NASDAQ:CELG) today announced the results of two post hoc sub-analyses of clinical trials for OTEZLA® (apremilast) at the 27th European Academy of Dermatology and Venereology (EADV) Congress in Paris, France. Findings suggest OTEZLA offered meaningful improvements in outcomes important to patients with moderate to severe plaque psoriasis, which may …
July, 2018
-
26 July
Revlimid in Combination with Rituximab Significantly Improved Progression-Free Survival in Phase 3 Lymphoma Study
SUMMIT, N.J.–(BUSINESS WIRE)–Celgene Corporation (NASDAQ: CELG) today announced results from a phase III, randomized, double-blind, international clinical study (AUGMENT). REVLIMID® (lenalidomide) plus rituximab (R2) achieved a highly statistically significant improvement in the primary endpoint of progression-free survival (PFS), compared to rituximab plus placebo, in the final PFS analysis. AUGMENT evaluated the …
-
10 July
Celgene’s Tecentriq Plus Abraxane Significantly Reduced the Risk of Disease Worsening or Death in Phase 3 TNBC Trial
SUMMIT, N.J.–(BUSINESS WIRE)–Celgene Corporation (NASDAQ:CELG) today announced that the Phase III IMpassion130 study, which was sponsored by Roche, met its co-primary endpoint of progression-free survival (PFS). This is the first phase III study to demonstrate a statistically significant PFS improvement in first-line metastatic or unresectable locally advanced triple negative breast …